- Home
- ASND vs TFX Comparison
ASND vs TFX Comparison
Compare ASND & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- TFX
- Stock Information
- Founded
- ASND 2006
- TFX 1943
- Country
- ASND Denmark
- TFX United States
- Employees
- ASND N/A
- TFX N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- TFX Medical/Dental Instruments
- Sector
- ASND Health Care
- TFX Health Care
- Exchange
- ASND Nasdaq
- TFX Nasdaq
- Market Cap
- ASND 9.9B
- TFX 8.3B
- IPO Year
- ASND 2015
- TFX N/A
- Fundamental
- Price
- ASND $151.43
- TFX $140.30
- Analyst Decision
- ASND Strong Buy
- TFX Hold
- Analyst Count
- ASND 14
- TFX 9
- Target Price
- ASND $201.79
- TFX $193.88
- AVG Volume (30 Days)
- ASND 409.7K
- TFX 1.6M
- Earning Date
- ASND 05-01-2025
- TFX 05-01-2025
- Dividend Yield
- ASND N/A
- TFX 0.97%
- EPS Growth
- ASND N/A
- TFX N/A
- EPS
- ASND N/A
- TFX 1.48
- Revenue
- ASND $376,478,932.00
- TFX $3,047,324,000.00
- Revenue This Year
- ASND $61.43
- TFX $3.37
- Revenue Next Year
- ASND $73.07
- TFX $4.13
- P/E Ratio
- ASND N/A
- TFX $94.42
- Revenue Growth
- ASND 36.34
- TFX 2.45
- 52 Week Low
- ASND $111.09
- TFX $128.55
- 52 Week High
- ASND $169.37
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- ASND 47.14
- TFX 40.93
- Support Level
- ASND $143.81
- TFX $135.20
- Resistance Level
- ASND $161.91
- TFX $140.98
- Average True Range (ATR)
- ASND 6.32
- TFX 3.07
- MACD
- ASND -1.66
- TFX 1.41
- Stochastic Oscillator
- ASND 29.81
- TFX 66.26
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.